Research
The effect of varying analytical methods on estimates of anti-malarial clinical efficacy
-
* Corresponding author: Ric N Price rnp@menzies.edu.au
1 Department of Epidemiology, School of Public Health, University of California, Berkeley, California, USA
2 Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
3 Shoklo Malaria Research Unit, Mae Sot, Thailand
4 Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
5 Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Churchill Hospital, Oxford, UK
6 International Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
Malaria Journal 2009, 8:77 doi:10.1186/1475-2875-8-77
Published: 22 April 2009Additional files
Additional file 1:
Characteristics and treatment outcomes of the clinical trials. Abbreviations: AL = artemether-lumefantrine; AM = artemether; AP: atovaquone-proguanil; AQ = amodiaquine; AS = artesunate; CQ = chlorquine; DP = dihydroartemisinin-piperaquine; MQ = mefloquine; SP = sulfadoxine-pyramethamine; ACPR = adequate clinical and parasitological response; ETF = early treatment failure; LCF = late clinical failure; LPF = late parasitological failure
Format: DOC Size: 161KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional file 2:
Estimates of the risk of failure according to treatment arm, derived by intention to treat (ITT), modified Intention to Treat (mITT) and per protocol (PP) analysis methods. Abbreviations: AL = artemether-lumefantrine; AM = artemether; AP: atovaquone-proguanil; AQ = amodiaquine; AS = artesunate; CQ = chlorquine; DP = dihydroartemisinin-piperaquine; MQ = mefloquine; SP = sulfadoxine-pyramethamine
Format: DOC Size: 239KB Download file
This file can be viewed with: Microsoft Word Viewer